세계의 mRNA 백신 및 치료제 시장 규모 조사 : 백신 유형별, 용도별, 치료 유형별, 최종사용자별, 지역별 예측(2022-2032년)

Global mRNA Vaccines and Therapeutics Market is valued at approximately USD 46.8 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.5% over the forecast period 2024-2032. Messenger ribonucleic acid (mRNA) represents a single-stranded ribonucleic acid (RNA) type crucial in the transfer of genetic information for protein production. mRNA-based therapeutics and vaccines have surfaced as groundbreaking alternatives to traditional treatment methodologies, gaining immense traction during the COVID-19 pandemic for their efficacy in addressing not only COVID-19 but also a multitude of other conditions including infectious diseases, cancer, and genetic disorders.

The rising prevalence of chronic and infectious diseases is driving significant growth in the global mRNA vaccines and therapeutics market, as these innovative treatments offer new ways to combat a range of health challenges. Chronic diseases such as cancer, cardiovascular diseases, and diabetes are becoming more common due to ageing populations and lifestyle factors. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide, highlighting the need for effective treatments. Simultaneously, infectious diseases like COVID-19 have underscored the importance of rapid vaccine development. The success of mRNA vaccines against COVID-19, such as those developed by Pfizer-BioNTech and Moderna, has demonstrated the potential of mRNA technology to quickly and effectively respond to infectious disease outbreaks. Moreover, the expansion into emerging markets, technological advancements in mRNA synthesis and manufacturing, and rising investment from both public and private sectors present various lucrative opportunities over the forecast years. However, the regulatory framework for market authorization, high production costs and infrastructure requirements are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global mRNA Vaccines and Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global mRNA Vaccines and Therapeutics Market in terms of revenue. The market growth in the region is being attributed to factors including advanced biotechnology infrastructure, significant investment in research and development, and the presence of key industry players like Moderna and Pfizer-BioNTech. The region's leadership in developing and distributing mRNA vaccines during the COVID-19 pandemic has solidified its position, with the U.S. accounting for a large share of the market. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increasing healthcare investments, rising demand for innovative treatments, and growing awareness of the potential benefits of mRNA technology. Countries such as China, Japan, and South Korea are investing heavily in biotechnology and expanding their capabilities to develop and produce mRNA-based treatments.

Major market players included in this report are:

• Pfizer Inc.
• Moderna, Inc.
• BioNTech SE
• GlaxoSmithKline
• Daiichi Sankyo
• Ribometrix Inc.
• Genentech
• Eli Lilly and Company
• Strand Therapeutics
• CureVac N.V.
• Arcturus Therapeutics
• Translate Bio
• Alnylam Pharmaceuticals
• Sanofi
• AstraZeneca

The detailed segments and sub-segment of the market are explained below:

By Vaccine Type:

• Self-amplifying mRNA-based Vaccines
• Conventional Non-amplifying mRNA-based Vaccines

By Application:

• Cancer
• Infectious Diseases
• Autoimmune Diseases
• Other Applications

By Treatment Type:

• Monoclonal Antibody
• Gene Therapy
• Cell Therapy
• Other Treatment Types

By End User:

• Research Laboratories and Organizations
• Hospitals and Clinics
• Other End Users

By Region:

North America:

• U.S.
• Canada

Europe:

• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific:

• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America:

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa:

• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global mRNA Vaccines and Therapeutics Market Executive Summary

• 1.1. Global mRNA Vaccines and Therapeutics Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Vaccine Type
  • 1.3.2. By Application
  • 1.3.3. By Treatment Type
  • 1.3.4. By End User
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global mRNA Vaccines and Therapeutics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global mRNA Vaccines and Therapeutics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising prevalence of chronic and infectious diseases
  • 3.1.2. Growth in R&D activities and strategic partnerships
  • 3.1.3. Increased demand for new vaccines and therapeutics
• 3.2. Market Challenges
  • 3.2.1. Regulatory framework for market authorization
  • 3.2.2. High production costs and infrastructure requirements
• 3.3. Market Opportunities
  • 3.3.1. Expansion into emerging markets
  • 3.3.2. Technological advancements in mRNA synthesis and manufacturing
  • 3.3.3. Rising investment from both public and private sectors

Chapter 4. Global mRNA Vaccines and Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Vaccine Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global mRNA Vaccines and Therapeutics Market: Vaccine Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Self-amplifying mRNA-based Vaccines
  • 5.2.2. Conventional Non-amplifying mRNA-based Vaccines

Chapter 6. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Application 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global mRNA Vaccines and Therapeutics Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Cancer
  • 6.2.2. Infectious Diseases
  • 6.2.3. Autoimmune Diseases
  • 6.2.4. Other Applications

Chapter 7. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Treatment Type 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global mRNA Vaccines and Therapeutics Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Monoclonal Antibody
  • 7.2.2. Gene Therapy
  • 7.2.3. Cell Therapy
  • 7.2.4. Other Treatment Types

Chapter 8. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by End User 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global mRNA Vaccines and Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Research Laboratories and Organizations
  • 8.2.2. Hospitals and Clinics
  • 8.2.3. Other End Users

Chapter 9. Global mRNA Vaccines and Therapeutics Market Size & Forecasts by Region 2022-2032

• 9.1. North America mRNA Vaccines and Therapeutics Market
  • 9.1.1. U.S. mRNA Vaccines and Therapeutics Market
    • 9.1.1.1. Vaccine Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Application breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Treatment Type breakdown size & forecasts, 2022-2032
    • 9.1.1.4. End User breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada mRNA Vaccines and Therapeutics Market
• 9.2. Europe mRNA Vaccines and Therapeutics Market
  • 9.2.1. U.K. mRNA Vaccines and Therapeutics Market
  • 9.2.2. Germany mRNA Vaccines and Therapeutics Market
  • 9.2.3. France mRNA Vaccines and Therapeutics Market
  • 9.2.4. Spain mRNA Vaccines and Therapeutics Market
  • 9.2.5. Italy mRNA Vaccines and Therapeutics Market
  • 9.2.6. Rest of Europe mRNA Vaccines and Therapeutics Market
• 9.3. Asia-Pacific mRNA Vaccines and Therapeutics Market
  • 9.3.1. China mRNA Vaccines and Therapeutics Market
  • 9.3.2. India mRNA Vaccines and Therapeutics Market
  • 9.3.3. Japan mRNA Vaccines and Therapeutics Market
  • 9.3.4. Australia mRNA Vaccines and Therapeutics Market
  • 9.3.5. South Korea mRNA Vaccines and Therapeutics Market
  • 9.3.6. Rest of Asia Pacific mRNA Vaccines and Therapeutics Market
• 9.4. Latin America mRNA Vaccines and Therapeutics Market
  • 9.4.1. Brazil mRNA Vaccines and Therapeutics Market
  • 9.4.2. Mexico mRNA Vaccines and Therapeutics Market
  • 9.4.3. Rest of Latin America mRNA Vaccines and Therapeutics Market
• 9.5. Middle East & Africa mRNA Vaccines and Therapeutics Market
  • 9.5.1. Saudi Arabia mRNA Vaccines and Therapeutics Market
  • 9.5.2. South Africa mRNA Vaccines and Therapeutics Market
  • 9.5.3. Rest of Middle East & Africa mRNA Vaccines and Therapeutics Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Pfizer Inc.
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Moderna, Inc.
  • 10.3.3. BioNTech SE
  • 10.3.4. GlaxoSmithKline
  • 10.3.5. Daiichi Sankyo
  • 10.3.6. Ribometrix Inc.
  • 10.3.7. Genentech
  • 10.3.8. Eli Lilly and Company
  • 10.3.9. Strand Therapeutics
  • 10.3.10. CureVac N.V.
  • 10.3.11. Arcturus Therapeutics
  • 10.3.12. Translate Bio
  • 10.3.13. Alnylam Pharmaceuticals
  • 10.3.14. Sanofi
  • 10.3.15. AstraZeneca

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes